Juniper Pharmaceuticals (Nasdaq: JNP) is developing therapeutics that address unmet and underserved medical needs in women's health. Our current product pipeline leverages our highly differentiated intravaginal ring ("IVR") technology with new formulations of existing pharmaceuticals, which we expect will offer multiple benefits to patients. Current 505(b)(2) candidates include:
- JNP-0101, an oxybutynin IVR for the treatment of overactive bladder in women;
- JNP-0201, a combination estradiol + progesterone IVR for hormone replacement therapy; and,
- JNP-0301, a natural progesterone IVR for the prevention of preterm birth.
We are leveraging the in-hous More >>